60 Degrees Pharmaceuticals, Inc. (SXTPW)
| Market Cap | 3.94M +7.7% |
| Revenue (ttm) | 1.31M +63.9% |
| Net Income | -8.09M |
| EPS | -7.92 |
| Shares Out | 2.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,002 |
| Open | 0.0459 |
| Previous Close | 0.0517 |
| Day's Range | 0.0459 - 0.0459 |
| 52-Week Range | 0.0301 - 0.1560 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About SXTPW
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zi... [Read more]
News
60 Degrees announces early enrollment of first patient in trial of tafenoquine
60 Degrees Pharmaceuticals (SXTP) announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy...
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-...
H.C. Wainwright downgrades 60 Degrees on ‘untenable’ spending
H.C. Wainwright downgraded 60 Degrees Pharmaceuticals (SXTP) to Neutral from Buy without a price target The firm cites Arakoda’s revenue trajectory and the company’s lack of pipeline visibility for th...
60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded 60 Degrees Pharmaceuticals (SXTP) to Neutral from Buy.
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious dise...
60 Degrees Pharmaceuticals Quarterly report: Q1 2026
60 Degrees Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 15, 2026.
60 Degrees Pharmaceuticals Earnings release: Q1 2026
60 Degrees Pharmaceuticals released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
60 Degrees Pharmaceuticals Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
ARAKODA's commercial growth is driven by both malaria prevention and emerging use in chronic babesiosis, with ongoing clinical trials aiming to expand its indications. Key milestones in 2024-2027 include diagnostic validation, interim clinical results, and a potential NDA submission.
60 Degrees Pharmaceuticals reports Arakoda availability on Runway Health website
60 Degrees Pharmaceuticals (SXTP) announced Arakoda for malaria prevention is now available for purchase on the Runway Health website, for U.S. travelers seeking more convenient protection against mal...
60 Degrees Pharmaceuticals Announces 2025 Annual Results
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Ph...
60 Degrees Pharmaceuticals Annual report: Q4 2025
60 Degrees Pharmaceuticals has published its Q4 2025 annual report on March 30, 2026.
60 Degrees submits NDIN to FDA for Australian Chestnut Extract
60 Degrees Pharmaceuticals (SXTP) announced it submitted a New Dietary Ingredient Notification, or NDIN, to the FDA for Australian Chestnut Extract on March 11. FDA has until May 25 to…
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.
60 Degrees reports all patients cured of babesiosis after tafenoquine treatment
60 Degrees Pharmaceuticals (SXTP) announced that three of three enrolled patients have been cured of babesiosis after completing the tafenoquine regimen in the Company’s trial of relapsing babesiosis ...
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
All three patients in 60 Degrees Pharma's expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review
60 Degrees expands access to Arakoda with GoodRx partnership
60 Degrees Pharmaceuticals (SXTP) announced a partnership with GoodRx (GDRX) to offer eligible consumers savings of up to 30% on Arakoda. Starting February 2, 2026, eligible patients can use GoodRx…
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategy Partnershi...
60 Degrees Pharmaceuticals to exercise option in agreement with FSU
60 Degrees Pharmaceuticals (SXTP) announced it has exercised the option in its agreement with Florida State University, FSU, to negotiate an exclusive license to use large-scale purification technique...
60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split
H.C. Wainwright adjusted the firm’s price target on 60 Degrees Pharmaceuticals (SXTP) to $24 from $6 and keeps a Buy rating on the shares after accounting for the 1-for-4 reverse…
Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today
60 Degrees Pharmaceuticals stock rallied on Thursday after the company announced a collaboration with Runway Health.
60 Degrees Pharmaceuticals announces partnership with Runway Health
60 Degrees Pharmaceuticals (SXTP) announced a partnership with Runway Health to expand pre-departure access to ARAKODA for prevention of malaria among international travelers through the Runway Health...
60 Degrees Pharmaceuticals Inc trading halted, news pending
19:50 EST 60 Degrees Pharmaceuticals (SXTP) Inc trading halted, news pending
60 Degrees Pharmaceuticals announces approval of 1-for-4 reverse stock split
60 Degree Pharmaceuticals announced that it will effect a one-for-four reverse stock split of its common stock, par value $0.0001 per share, that will become effective on January 20, 2026,…
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines ...
60 Degrees announces detection of babesia infection in 24% of patients in study
60 Degrees Pharmaceuticals (SXTP) announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients…